Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test

• Published in: Annals of laboratory medicine 2016, 36(1), , pp.42-48
• Main Authors: Li, Shuhua, Choi, Jae Lim, Guo, Long Zhe, Goh, Ri Young, Kim, Bo Ram, Woo, Kwang Sook, Kim, Moo Hyun, Han, Jin Yeong
• Format: Article
• Language: English
• Subjects: Aged; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Clopidogrel; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C19 - metabolism; Female; Genotype; Humans; Male; Middle Aged; Original; Phenotype; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests - instrumentation; Polymorphism, Genetic; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; 병리학
• ISSN: 2234-3806; 2234-3814
• DOI: 10.3343/alm.2016.36.1.42

An association has been reported between CYP2C19 polymorphism and the altered antiplatelet activity of clopidogrel. We investigated this association using the newly introduced platelet function analyzer (PFA)-200 (INNOVANCE PFA-200 System; Siemens Healthcare, Germany) P2Y test. Polymorphisms of CYP2C19*2, *3, *17 and the degree of inhibition of platelet function were determined in 83 patients. Three different platelet function tests were used to evaluate the degree of platelet inhibition and to check the association with genotype. The post-procedure PFA-200 values of extensive metabolizers (EM) patients (285.3±38.8) were higher than those of intermediate metabolizers (IM) and poor metabolizers (PM) patients (227.7±98.3 and 133.7±99.2, respectively; P=0.024). Light transmittance aggregometry (LTA) and the VerifyNow system showed that the post-procedure values for EM patients were lower than those of IM and PM patients (LTA: 24.4±15.7, 34.1±17.6, and 42.2±16.9, respectively, P